RESEARCH TRIANGLE PARK, N.C. — February 2, 2026 — Leads & Copy — Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company focused on gene therapies for inherited retinal diseases (IRDs), announced its leadership team will participate in several upcoming ophthalmology and industry conferences.
Opus Genetics leadership will engage in discussions at the Collaborative Community on Ophthalmic Innovation (CCOI) in Hong Kong from February 3-4, 2026, focusing on emerging treatment approaches and clinical insights in retinal disease.
The company will also participate in the Asia-Pacific Academy of Ophthalmology Congress (APAO) in Hong Kong from February 5-8, 2026, to discuss advances in gene therapy and strategies for treating inherited retinal disorders.
Chris Ernst, Chief Technology Officer of Opus Genetics, will present at the Advanced Therapies Week Conference in San Diego, CA, on February 11, 2026, from 10:30 – 11:00 AM PT. The presentation is titled: Building scalable viral vector manufacturing models.
Mark Pennesi, M.D., Ph.D., Professor of Ophthalmology, School of Medicine, OHSU Casey Eye Institute, will present preliminary results from the sentinel patient in a Phase 1b/2a clinical study of OPGx-BEST1 gene therapy for the treatment of BVMD and ARB due to BEST1 mutations at The Macula Society Annual Meeting in San Diego, CA, on February 27, 2026, from 7:15 – 7:20 AM PT.
Opus Genetics is developing durable, one-time treatments designed to address the underlying genetic causes of severe retinal disorders. The company’s pipeline includes seven AAV-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with additional candidates targeting RHO, CNGB1, RDH12, NMNAT1, and MERTK. Opus Genetics is also advancing Phentolamine Ophthalmic Solution 0.75%, an approved small-molecule therapy for pharmacologically induced mydriasis, with additional potential indications in presbyopia and low-light visual disturbances following keratorefractive surgery.
Opus Genetics is based in Research Triangle Park, NC.
Source: Opus Genetics
